A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Trial Profile

A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Paclitaxel trevatide (Primary) ; Trastuzumab
  • Indications Advanced breast cancer; Brain metastases
  • Focus Therapeutic Use
  • Acronyms GRABM-B
  • Sponsors AngioChem
  • Most Recent Events

    • 03 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2015 Results of a biomarker sub-study (n=10) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015.
    • 02 Jun 2015 Results of biomarker substudy (n=10) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top